Pharma / Biotech

Citing Alcohol Risks, FDA Orders Safety Labeling Changes for Addyi

The FDA has issued a safety labeling change order to Sprout Pharmaceuticals for flibanserin (Addyi), requiring the company to revise safety information on the risks posed by concomitant use of alcohol in women taking the medication.

Source link

Related posts

Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food/herb-drug interaction.


QVAR (Beclomethasone Dipropionate) Aerosol, Metered [A-S Medication Solutions]


BISOPROLOL FUMARATE Tablet, Film Coated [Mylan Pharmaceuticals Inc.]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy